The Use of Family History Questionnaires: An Examination of Genetic Risk Estimates and Genetic Testing Eligibility in the Non-responder Population
- 167 Downloads
The use of mailed family history questionnaires (FHQs) has previously been established to be an effective method for obtaining family history information for the triage of patients for genetic counseling and genetic testing of hereditary breast and ovarian cancer syndrome; yet only 53% of patients complete their FHQ within 6 months from the date of mailing (Armel et al. Journal of Genetic Counseling, 18(4):366–378, 2009). Although literature exists evaluating why women may not attend genetic counseling, no data are currently available examining genetic risk or genetic testing eligibility in the population of patients not returning their FHQ (non-responders). Concern exists that if non-responders are not followed-up for the purpose of triage for genetic counseling, individuals at high-risk for a hereditary cancer syndrome may be missed. This article explores the demographics of the non-responder population to assess genetic risk estimates for mutations in the BRCA1 and BRCA2 genes and genetic testing eligibility as compared to a responder population of patients who completed a mailed FHQ. A total of 430 pedigrees were obtained, 215 from non-responders and 215 from responders. Results of this study indicate that 69% of non-responders were either unreachable by telephone (42%), declined an appointment (19%), or were previously seen in another center for a genetic counseling visit (8%). Additionally, results indicate that non-responders are less likely to be eligible for genetic testing (40%) as compared to responders (57%) (p = 0.0004). Together these data shed light on a population of patients for which limited information exists and suggest that we question how and to what extent clinics should pursue non-responders, particularly in light of global reductions in health care funding.
KeywordsGenetic counseling Family history Questionnaire Attendance rate Genetic testing eligibility Genetic risk estimate Hereditary breast and ovarian cancer syndrome
- Antoniou, A. C., Pharoah, P. D., Narod, S., Risch, H. A., Eyfjord, J. E., Hopper, J. L., et al. (2005). Breast and ovarian cancer risks to carriers of the BRCA1 5382insC and 185delAG and BRCA2 6174delT mutations: a combined analysis of 22 population based studies. Journal of Medical Genetics, 42(7), 602–603.PubMedCrossRefGoogle Scholar
- Armstrong, K., Calzone, K., Stopfer, J., Fitzgerald, G., Coyne, J., & Weber, B. (2000). Factors associated with decisions about clinical BRCA1/2 testing. Cancer Epidemiology, Biomarkers & Prevention: A Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology, 9(11), 1251–1254.Google Scholar
- Berry, D. A., Iversen, E. S., Jr., Gudbjartsson, D. F., Hiller, E. H., Garber, J. E., Peshkin, B. N., et al. (2002). BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 20(11), 2701–2712.Google Scholar
- Brener, D., Schulz, C., Schluger, A., & Offit, K. (1996). A self-administered family history questionnaire (FHQ) utilized in an outpatient setting to assess cancer risk. American Journal of Human Genetics, 59(A333).Google Scholar
- Canadian Cancer Society. (2009a). Canadian cancer statistics. Retrieved 4/26/2010, 2010, from http://www.cancer.ca/Canada-wide/Aboutcancer/Cancerstatistics/~/media/CCS/Canadawide/FilesList/Englishfilesheading/pdfnotinpublicationssection/Stats2009ECdnCancer.ashx.
- Canadian Cancer Society. (2009b). Breast cancer statistics. Retrieved 4/26/2010, 2010, from http://www.cancer.ca/Canada-wide/Aboutcancer/Cancerstatistics/Statsataglance/Breastcancer.aspx?sc_lang=en.
- Ford, D., Easton, D. F., Stratton, M., Narod, S., Goldgar, D., Devilee, P., et al. (1998). Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. the breast cancer linkage consortium. American Journal of Human Genetics, 62(3), 676–689.PubMedCrossRefGoogle Scholar
- Foster, C., Evans, D. G., Eeles, R., Eccles, D., Ashley, S., Brooks, L., et al. (2004). Non-uptake of predictive genetic testing for BRCA1/2 among relatives of known carriers: Attributes, cancer worry, and barriers to testing in a multicenter clinical cohort. Genetic Testing, 8(1), 23–29.PubMedCrossRefGoogle Scholar
- Julian-Reynier, C., Sobol, H., Sevilla, C., Nogues, C., Bourret, P., & French Cancer Genetic Network. (2000). Uptake of hereditary breast/ovarian cancer genetic testing in a french national sample of BRCA1 families. the french cancer genetic network. Psycho-Oncology, 9(6), 504–510.PubMedCrossRefGoogle Scholar
- Lerman, C., Daly, M., Masny, A., & Balshem, A. (1994). Attitudes about genetic testing for breast-ovarian cancer susceptibility. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 12(4), 843–850.Google Scholar
- Lerman, C., Narod, S., Schulman, K., Hughes, C., Gomez-Caminero, A., Bonney, G., et al. (1996). BRCA1 testing in families with hereditary breast-ovarian cancer. A prospective study of patient decision making and outcomes. JAMA The Journal of the American Medical Association, 275(24), 1885–1892.PubMedCrossRefGoogle Scholar
- Struewing, J. P., Lerman, C., Kase, R. G., Giambarresi, T. R., & Tucker, M. A. (1995). Anticipated uptake and impact of genetic testing in hereditary breast and ovarian cancer families. Cancer Epidemiology, Biomarkers & Prevention: A Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology, 4(2), 169–173.Google Scholar